JP2023518052A5 - - Google Patents

Info

Publication number
JP2023518052A5
JP2023518052A5 JP2022555741A JP2022555741A JP2023518052A5 JP 2023518052 A5 JP2023518052 A5 JP 2023518052A5 JP 2022555741 A JP2022555741 A JP 2022555741A JP 2022555741 A JP2022555741 A JP 2022555741A JP 2023518052 A5 JP2023518052 A5 JP 2023518052A5
Authority
JP
Japan
Prior art keywords
approximately
concentration
present
hypoglycemia
aqueous liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022555741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518052A (ja
JP7834025B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/056651 external-priority patent/WO2021185821A1/en
Publication of JP2023518052A publication Critical patent/JP2023518052A/ja
Publication of JP2023518052A5 publication Critical patent/JP2023518052A5/ja
Application granted granted Critical
Publication of JP7834025B2 publication Critical patent/JP7834025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022555741A 2020-03-16 2021-03-16 グルカゴン類縁体の液体製剤 Active JP7834025B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20163408.6 2020-03-16
EP20163408 2020-03-16
PCT/EP2021/056651 WO2021185821A1 (en) 2020-03-16 2021-03-16 Liquid formulations of glucagon analogues

Publications (3)

Publication Number Publication Date
JP2023518052A JP2023518052A (ja) 2023-04-27
JP2023518052A5 true JP2023518052A5 (https=) 2024-03-26
JP7834025B2 JP7834025B2 (ja) 2026-03-23

Family

ID=70008261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555741A Active JP7834025B2 (ja) 2020-03-16 2021-03-16 グルカゴン類縁体の液体製剤

Country Status (22)

Country Link
US (2) US20210283053A1 (https=)
EP (1) EP4121003B1 (https=)
JP (1) JP7834025B2 (https=)
CN (1) CN115279341B (https=)
AR (1) AR121581A1 (https=)
AU (1) AU2021236878B2 (https=)
BR (1) BR112022018462A2 (https=)
CA (1) CA3171184A1 (https=)
CL (1) CL2022002472A1 (https=)
CO (1) CO2022014452A2 (https=)
ES (1) ES3041327T3 (https=)
HR (1) HRP20251267T1 (https=)
HU (1) HUE073401T2 (https=)
IL (1) IL295977A (https=)
MX (1) MX2022011227A (https=)
PE (1) PE20230258A1 (https=)
PH (1) PH12022552457A1 (https=)
PL (1) PL4121003T3 (https=)
RS (1) RS67245B1 (https=)
TW (1) TW202200190A (https=)
UA (1) UA129439C2 (https=)
WO (1) WO2021185821A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI880227B (zh) * 2022-05-30 2025-04-11 丹麥商西蘭製藥公司 澱粉素類似物之液體調配物
WO2025056677A1 (en) 2023-09-15 2025-03-20 Zealand Pharma A/S Dasiglucagon for use in the treatment of congenital hyperinsulinism

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
IN2015DN00544A (https=) * 2012-07-23 2015-06-26 Zealand Pharma As
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
BR112017014994B1 (pt) 2015-02-17 2023-12-19 Eli Lilly And Company Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
WO2017053822A1 (en) 2015-09-23 2017-03-30 Behavioral Recognition Systems, Inc. Detected object tracker for a video analytics system
GB201710822D0 (en) 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia
US20190275110A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid

Similar Documents

Publication Publication Date Title
US20240342249A1 (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
US9381247B2 (en) Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
BE1009408A5 (fr) Formulations d'analogues de l'insuline.
FR2943538A1 (fr) Formulation a action rapide d'insuline recombinante humaine
RU2320343C2 (ru) Способ лечения диабета
JP2023518052A5 (https=)
CN110446496A (zh) 用于治疗糖尿病的系统、组合物和方法
HRP20251267T1 (hr) Tekuće formulacije glukagonskih analoga
US11590205B2 (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
KR20100038322A (ko) 당뇨병 치료 방법
CA2796567C (en) Composition comprising insulin and herbal oil for transdermal or transmucosal administration
ZA200500710B (en) A platform for transdermal formulations (PTF).
NZ791927B2 (en) Liquid formulations of glucagon analogues
WO2014059363A1 (en) Oral solution formulations of aripiprazole
JP7518149B2 (ja) 高濃度インスリン製剤
RU2442585C2 (ru) Способ лечения диабета
JP2026015586A (ja) ペメトレキセド製剤
EP4727651A1 (en) Method of enhancing the systemic hypoglycemic effect of topically applied insulin with the use of prostaglandin analogues: a novel fixed combination eye drop formulation of insulin and prostaglandin analogue for the lowering of blood glucose level
WO2025068976A1 (en) Compositions comprising insulin agonists, and said compositions for use in the treatment of diabetes or obesity
HK40101667A (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
CN118056841A (zh) 一种长效胰岛素衍生物及其制备方法和用途
KR20230055994A (ko) 당뇨병 또는 당뇨합병증의 치료를 위한 4-헥실레조르시놀의 용도
JP2004231557A (ja) エピネフリン含有抗腫瘍剤
US20260083822A1 (en) Topical Ocular Insulin Delivery Enhanced by Prostaglandin Analogues
BE1013507A5 (fr) Formulations d'analogues de l'insuline.